Latest news with #ShagunSinghChadha
Business Insider
17-07-2025
- Business
- Business Insider
Penumbra (PEN) Gets a Buy from RBC Capital
In a report released on July 15, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Penumbra, with a price target of $330.00. The company's shares closed yesterday at $234.41. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Singh Chadha is an analyst with an average return of -1.0% and a 47.96% success rate. Singh Chadha covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Medtronic, and Boston Scientific. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Penumbra with a $316.67 average price target, implying a 35.09% upside from current levels. In a report released yesterday, Robert W. Baird also maintained a Buy rating on the stock with a $283.00 price target. Based on Penumbra's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $324.14 million and a net profit of $39.22 million. In comparison, last year the company earned a revenue of $278.66 million and had a net profit of $11 million
Business Insider
17-07-2025
- Business
- Business Insider
RBC Capital Remains a Buy on Insulet (PODD)
RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Insulet on July 15 and set a price target of $330.00. The company's shares closed yesterday at $288.27. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Singh Chadha is an analyst with an average return of -1.0% and a 47.96% success rate. Singh Chadha covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Medtronic, and Boston Scientific. Currently, the analyst consensus on Insulet is a Strong Buy with an average price target of $340.84, representing a 18.24% upside. In a report released on July 14, BTIG also maintained a Buy rating on the stock with a $350.00 price target. Based on Insulet's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $569 million and a net profit of $35.4 million. In comparison, last year the company earned a revenue of $441.7 million and had a net profit of $51.5 million Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PODD in relation to earlier this year. Last month, LUCIANA BORIO, a Director at PODD sold 481.00 shares for a total of $147,056.13.
Business Insider
17-07-2025
- Business
- Business Insider
RBC Capital Sticks to Their Buy Rating for Stryker (SYK)
In a report released on July 15, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Stryker, with a price target of $435.00. The company's shares closed yesterday at $390.87. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Singh Chadha covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Medtronic, and Boston Scientific. According to TipRanks, Singh Chadha has an average return of -1.0% and a 47.96% success rate on recommended stocks. Stryker has an analyst consensus of Strong Buy, with a price target consensus of $435.94, which is an 11.53% upside from current levels. In a report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $450.00 price target. SYK market cap is currently $149.6B and has a P/E ratio of 52.83. Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SYK in relation to earlier this year. Most recently, in May 2025, William E. Berry, the VP & CAO of SYK sold 1,241.00 shares for a total of $482,190.55.
Business Insider
17-07-2025
- Business
- Business Insider
RBC Capital Sticks to Its Buy Rating for Johnson & Johnson (JNJ)
RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Johnson & Johnson on July 15 and set a price target of $181.00. The company's shares closed yesterday at $164.78. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Singh Chadha is an analyst with an average return of -1.0% and a 47.96% success rate. Singh Chadha covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Medtronic, and Boston Scientific. In addition to RBC Capital, Johnson & Johnson also received a Buy from Citi's Joanne Wuensch in a report issued yesterday. However, on the same day, Bank of America Securities maintained a Hold rating on Johnson & Johnson (NYSE: JNJ). Based on Johnson & Johnson's latest earnings release for the quarter ending March 30, the company reported a quarterly revenue of $21.89 billion and a net profit of $11 billion. In comparison, last year the company earned a revenue of $21.38 billion and had a net profit of $3.26 billion
Globe and Mail
02-04-2025
- Business
- Globe and Mail
RBC Capital Keeps Their Buy Rating on Johnson & Johnson (JNJ)
RBC Capital analyst Shagun Singh Chadha reiterated a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target of $181.00. The company's shares closed yesterday at $153.25. Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks. Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter. Singh Chadha covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Inspire Medical Systems, and Boston Scientific. According to TipRanks, Singh Chadha has an average return of -0.3% and a 46.23% success rate on recommended stocks. Johnson & Johnson has an analyst consensus of Moderate Buy, with a price target consensus of $168.42, implying a 9.90% upside from current levels. In a report released yesterday, UBS also reiterated a Buy rating on the stock with a $180.00 price target. Based on Johnson & Johnson's latest earnings release for the quarter ending December 29, the company reported a quarterly revenue of $22.52 billion and a net profit of $3.43 billion. In comparison, last year the company earned a revenue of $21.4 billion and had a net profit of $4.05 billion Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JNJ in relation to earlier this year. Most recently, in February 2025, Robert J Decker, the VP Corporate Controller of JNJ sold 6,999.00 shares for a total of $1,160,994.12.
